MSH6 LOSS

CI-VAR-00002460Explore in graph →CIViC 809

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Transitional Cell Carcinoma1
MSH6 LOSS	Anti-PD-1 Monoclonal Antibody MEDI0680 + DurvalumabCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID1878 Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs2, E226, E580*) and in MSH6 (R361H) by panel… (full text at CIViC) PMID 26674132 · Castro et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.